(NYSE: STVN) Stevanato Group Spa's forecast annual revenue growth rate of 1.32% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 11.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.91%.
Stevanato Group Spa's revenue in 2026 is $1,395,625,882.On average, 12 Wall Street analysts forecast STVN's revenue for 2026 to be $393,998,139,336, with the lowest STVN revenue forecast at $376,736,114,784, and the highest STVN revenue forecast at $407,626,053,456. On average, 12 Wall Street analysts forecast STVN's revenue for 2027 to be $433,367,669,016, with the lowest STVN revenue forecast at $411,260,163,888, and the highest STVN revenue forecast at $451,235,378,640.
In 2028, STVN is forecast to generate $474,554,253,912 in revenue, with the lowest revenue forecast at $447,601,268,208 and the highest revenue forecast at $500,901,554,544.